Webster K Cavenee

List of Publications by Year in Descending Order

195 papers	41,282 citations	80 h-index	203 g-index
203 ext. papers	46,599 ext. citations	11.8 avg, IF	7.02 L-index

#	Paper	IF	Citations
195	Immune evasion in HPV head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
194	Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. *Molecular Cancer Research*, **2020**, 18, 1142-1152	6.6	9
193	Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12324-12331	11.5	9
192	Tumour predisposition and cancer syndromes as models to study gene-environment interactions. *Nature Reviews Cancer*, **2020**, 20, 533-549	31.3	32
191	mTOR complex 2 is an integrator of cancer metabolism and epigenetics. *Cancer Letters*, **2020**, 478, 1-7	9.9	19
190	Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review. *Acta Histochemica Et Cytochemica*, **2020**, 53, 1-10	1.9	11
189	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. *Pharmacological Research*, **2020**, 155, 104695	10.2	13
188	Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. *Cancer Gene Therapy*, **2020**, 27, 301-310	5.4	12
187	Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule. *ACS Chemical Neuroscience*, **2019**, 10, 1121-1123	5.7	10
186	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 10009-10018	11.5	23
185	MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 5687-5692	11.5	21
184	Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6308-6312	11.5	72
183	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. *Cell Metabolism*, **2019**, 30, 525-538.e8	24.6	65
182	mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma. *Journal of Biological Chemistry*, **2019**, 294, 19740-19751	5.4	12
181	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. *Cancer Cell*, **2019**, 35, 504-518.e7	24.3	53
180	Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review. *JAMA Neurology*, **2019**, 76, 492-500	17.2	21
179	Metabolic reprogramming in the pathogenesis of glioma: Update. *Neuropathology*, **2019**, 39, 3-13	2	17

178	Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. *Cancer Research*, **2019**, 79, 1239-1251	10.1	41
177	FHL2 interacts with EGFR to promote glioblastoma growth. *Oncogene*, **2018**, 37, 1386-1398	9.2	18
176	Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. *Journal of Visualized Experiments*, **2018**,	1.6	3
175	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. *Clinical Cancer Research*, **2018**, 24, 737-743	12.9	97
174	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. *Autophagy*, **2018**, 14, 1845-1846	10.2	22
173	Reply to Yoshida: Delineating critical roles of MDA-9 in protective autophagy-mediated anoikis resistance in human glioma stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E7654-E7655	11.5	1
172	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. *Cell Death and Differentiation*, **2018**, 25, 1885-1904	12.7	17
171	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 5768-5773	11.5	67
170	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature*, **2017**, 543, 122-125	50.4	260
169	Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 6812-6817	11.5	21
168	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 370-375	11.5	57
167	Glioblastoma cellular cross-talk converges on NF-Β to attenuate EGFR inhibitor sensitivity. *Genes and Development*, **2017**, 31, 1212-1227	12.6	38
166	Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. *Npj Precision Oncology*, **2017**, 1, 1	9.8	63
165	Going viral? Linking the etiology of human prostate cancer to the long noncoding RNA and oncogenic viruses. *EMBO Molecular Medicine*, **2017**, 9, 1327-1330	12	9
164	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. *Journal of Controlled Release*, **2016**, 244, 14-23	11.7	28
163	Cancer metabolism as a central driving force of glioma pathogenesis. *Brain Tumor Pathology*, **2016**, 33, 161-8	3.2	27
162	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. *Cancer Cell*, **2016**, 29, 563-573	24.3	111
161	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, **2016**, 131, 803-20	14.3	8580

160	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. *Cancer Cell*, **2016**, 30, 683-693	24.3	149
159	mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. *BioEssays*, **2016**, 38, 839-44	4.1	13
158	A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. *Cancer Research*, **2015**, 75, 394-404	10.1	40
157	Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 9406-11	11.5	79
156	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 8403-8	11.5	179
155	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. *Nature Reviews Cancer*, **2015**, 15, 302-10	31.3	227
154	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. *Molecular Cell*, **2015**, 60, 307-18	17.6	127
153	mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. *Brain Pathology*, **2015**, 25, 755-9	6	19
152	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. *Oncotarget*, **2015**, 6, 11751-67	3.3	9
151	Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 1107-12	11.5	112
150	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. *Science*, **2014**, 343, 72-6	33.3	316
149	Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. *Cancer Research*, **2014**, 74, 1429-39	10.1	53
148	mTORC2 in the center of cancer metabolic reprogramming. *Trends in Endocrinology and Metabolism*, **2014**, 25, 364-73	8.8	90
147	Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. *Oncology Letters*, **2014**, 7, 933-940	2.6	6
146	Glioblastoma: from molecular pathology to targeted treatment. *Annual Review of Pathology: Mechanisms of Disease*, **2014**, 9, 1-25	34	346
145	EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. *Journal of Clinical Investigation*, **2014**, 124, 3741-56	15.9	58
144	Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. *Oncotarget*, **2014**, 5, 882-93	3.3	88
143	Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. *Cancer Biology and Medicine*, **2014**, 11, 255-63	5.2	36

142	Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. *International Journal of Cancer*, **2013**, 132, 509-20	7.5	36
141	mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. *Cell Metabolism*, **2013**, 18, 726-39	24.6	264
140	The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. *Clinical Cancer Research*, **2013**, 19, 5722-32	12.9	35
139	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. *Carcinogenesis*, **2013**, 34, 725-38	4.6	68
138	De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. *Cancer Discovery*, **2013**, 3, 534-47	24.4	90
137	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. *Cell Metabolism*, **2013**, 17, 1000-1008	24.6	105
136	A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. *PLoS Genetics*, **2013**, 9, e1003253	6	77
135	PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 4339-44	11.5	49
134	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. *Cancer Biology and Medicine*, **2013**, 10, 192-205	5.2	37
133	Emerging insights into the molecular and cellular basis of glioblastoma. *Genes and Development*, **2012**, 26, 756-84	12.6	388
132	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14164-9	11.5	85
131	Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 3018-23	11.5	81
130	Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer. *Cancer Prevention Research*, **2012**, 5, 1073-4	3.2	2
129	Heterogeneity maintenance in glioblastoma: a social network. *Cancer Research*, **2011**, 71, 4055-60	10.1	326
128	Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of EGFR. *Journal of Proteome Research*, **2011**, 10, 1343-52	5.6	37
127	MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. *Molecular Cancer Research*, **2011**, 9, 1100-11	6.6	134
126	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. *Journal of Experimental Medicine*, **2011**, 208, 2657-73	16.6	50
125	Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. *Cancer Discovery*, **2011**, 1, 524-38	24.4	218

124	Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 15984-9	11.5	47
123	Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. *Journal of Cell Science*, **2011**, 124, 2938-50	5.3	31
122	Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. *Journal of Clinical Investigation*, **2011**, 121, 161-73	15.9	110
121	Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFR-stimulated glioma tumorigenesis in mice and humans. *Journal of Clinical Investigation*, **2011**, 121, 4670-84	15.9	92
120	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. *Chinese Journal of Cancer*, **2011**, 30, 5-12		86
119	Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. *PLoS ONE*, **2010**, 5, e10767	3.7	51
118	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. *Genes and Development*, **2010**, 24, 1731-45	12.6	385
117	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2616-21	11.5	56
116	KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. *Journal of the National Cancer Institute*, **2010**, 102, 1131-47	9.7	9
115	Escape from targeted inhibition: the dark side of kinase inhibitor therapy. *Cell Cycle*, **2010**, 9, 1661-2	4.7	11
114	Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. *Molecular BioSystems*, **2010**, 6, 1227-37		36
113	Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 5082-7	11.5	55
112	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. *Cancer Research*, **2009**, 69, 6889-98	10.1	120
111	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. *Cancer Research*, **2009**, 69, 4252-9	10.1	201
110	A drosophila model for EGFR-Ras and PI3K-dependent human glioma. *PLoS Genetics*, **2009**, 5, e1000374	6	145
109	Stem cells for treating glioblastoma: how close to reality?. *Neuro-Oncology*, **2009**, 11, 101	1	6
108	Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. *Cancer Cell*, **2008**, 13, 355-64	24.3	101
107	Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. *Clinical Cancer Research*, **2008**, 14, 488-93	12.9	83

106	Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. *Cell Cycle*, **2008**, 7, 837-41	4.7	11
105	Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. *Genome Research*, **2008**, 18, 46-59	9.7	95
104	Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. *Journal of Clinical Investigation*, **2007**, 117, 346-52	15.9	40
103	Malignant astrocytic glioma: genetics, biology, and paths to treatment. *Genes and Development*, **2007**, 21, 2683-710	12.6	1682
102	The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathologica*, **2007**, 114, 97-109	14.3	8119
101	Uncovering therapeutic targets for glioblastoma: a systems biology approach. *Cell Cycle*, **2007**, 6, 2750-4	4.7	55
100	The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. *Clinical Cancer Research*, **2007**, 13, 1911-25	12.9	59
99	PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 18085-90	11.5	45
98	Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. *Journal of Neurosurgery*, **2007**, 106, 407-16	3.2	23
97	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12867-72	11.5	328
96	The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. *Cancer Cell*, **2006**, 9, 379-90	24.3	55
95	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. *Cancer Research*, **2006**, 66, 7864-9	10.1	212
94	PCAF modulates PTEN activity. *Journal of Biological Chemistry*, **2006**, 281, 26562-8	5.4	155
93	Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. *Transgenic Research*, **2006**, 15, 595-614	3.3	14
92	Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. *Journal of Neuro-Oncology*, **2006**, 76, 23-30	4.8	48
91	PTEN: a novel anti-oncogenic function independent of phosphatase activity. *Cell Cycle*, **2005**, 4, 540-2	4.7	26
90	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *New England Journal of Medicine*, **2005**, 353, 2012-24	59.2	1211
89	Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 2703-6	11.5	97

88	Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. *Clinical Cancer Research*, **2005**, 11, 6390-9	12.9	98
87	Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. *Molecular Cancer Therapeutics*, **2005**, 4, 101-12	6.1	169
86	Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. *Molecular and Cellular Biology*, **2004**, 24, 8981-93	4.8	107
85	Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. *Brain Tumor Pathology*, **2004**, 21, 53-6	3.2	98
84	Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 2975-80	11.5	537
83	Methylation Profiling Identifies Epigenetic Markers for High-grade Gliomas. *Cancer Genomics and Proteomics*, **2004**, 1, 209-214	3.3	3
82	A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 639-44	11.5	138
81	Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8904-9	11.5	131
80	Preparing for serendipity. *Cancer Biology and Therapy*, **2003**, 2, 213-5	4.6	
79	The recessive nature of dominance. *Genes Chromosomes and Cancer*, **2003**, 38, 322-5	5	1
78	Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. *American Journal of Pathology*, **2003**, 162, 1083-93	5.8	271
77	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8164-9	11.5	409
76	Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 6505-10	11.5	127
75	CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. *Brain Pathology*, **2002**, 12, 12-20	6	30
74	Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. *International Journal of Cancer*, **2002**, 98, 398-408	7.5	115
73	A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. *Journal of Neurochemistry*, **2002**, 81, 575-88	6	3
72	Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. *Nature Genetics*, **2002**, 32, 245-53	36.3	541
71	Genetics and new approaches to cancer therapy. *Carcinogenesis*, **2002**, 23, 683-6	4.6	18

70	The WHO classification of tumors of the nervous system. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 215-25; discussion 226-9	3.1	1375
69	Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. *Cancer Research*, **2002**, 62, 6764-9	10.1	135
68	The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. *Journal of Biological Chemistry*, **2001**, 276, 46313-8	5.4	57
67	Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. *Journal of Neurosurgery*, **2001**, 95, 472-9	3.2	64
66	Malignant glioma: genetics and biology of a grave matter. *Genes and Development*, **2001**, 15, 1311-33	12.6	934
65	Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. *Nature Genetics*, **2000**, 24, 132-8	36.3	1138
64	IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. *Oncogene*, **2000**, 19, 2687-94	9.2	71
63	Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors. *Journal of Neuro-Oncology*, **2000**, 46, 17-22	4.8	11
62	Aberrant methylation of genes in low-grade astrocytomas. *Brain Tumor Pathology*, **2000**, 17, 49-56	3.2	57
61	Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP. *Genomics*, **2000**, 64, 195-202	4.3	19
60	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. *Oncogene*, **1999**, 18, 3936-43	9.2	97
59	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. *Oncogene*, **1999**, 18, 5239-45	9.2	53
58	Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. *Drug Resistance Updates*, **1999**, 2, 30-37	23.2	5
57	A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. *Genomics*, **1999**, 58, 254-62	4.3	68
56	Identification and validation of tumor suppressor genes. *Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications*, **1999**, 2, 1-10		11
55	Expression of vascular endothelial growth factor in human brain tumors. *Acta Neuropathologica*, **1998**, 96, 453-62	14.3	81
54	Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. *Genomics*, **1998**, 47, 187-99	4.3	289
53	Host microvasculature influence on tumor vascular morphology and endothelial gene expression. *American Journal of Pathology*, **1998**, 153, 1239-48	5.8	91

52	Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. *Journal of Biological Chemistry*, **1998**, 273, 20213-22	5.4	147
51	In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 9418-23	11.5	83
50	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. *Journal of Biological Chemistry*, **1997**, 272, 2927-35	5.4	434
49	Advances in the molecular genetics of gliomas. *Current Opinion in Oncology*, **1997**, 9, 215-22	4.2	47
48	Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo. *Journal of Investigative Dermatology*, **1997**, 108, 950	4.3	14
47	Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. *Oncogene*, **1997**, 14, 603-9	9.2	30
46	The expression of RET and its multiple splice forms in developing human kidney. *Oncogene*, **1997**, 14, 1811-8	9.2	31
45	Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. *Oncogene*, **1997**, 15, 2013-20	9.2	32
44	Expression and distribution of vascular endothelial growth factor protein in human brain tumors. *Acta Neuropathologica*, **1997**, 93, 109-17	14.3	155
43	Population variation at the polymorphic ApaLI restriction enzyme site in intron 5 of the WT1 gene. *Clinical Genetics*, **1996**, 50, 555-7	4	
42	cAMP effects on myogenic gene expression in rhabdomyosarcoma cells. *Experimental Cell Research*, **1996**, 227, 55-62	4.2	4
41	A common region of loss of heterozygosity in WilmsStumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. *Human Genetics*, **1996**, 97, 163-70	6.3	56
40	Molecular biology of malignant degeneration of astrocytoma. *Pediatric Neurosurgery*, **1996**, 24, 41-9	0.9	14
39	Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. *Genes Chromosomes and Cancer*, **1996**, 16, 254-60	5	27
38	Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. *Journal of Biological Chemistry*, **1996**, 271, 25639-45	5.4	127
37	p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. *Nature Medicine*, **1995**, 1, 570-7	50.5	376
36	EGFR gene amplification--rearrangement in human glioblastomas. *International Journal of Cancer*, **1995**, 62, 145-8	7.5	94
35	A constitutional BWS-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in WilmsStumors. *Genes Chromosomes and Cancer*, **1995**, 12, 1-7	5	21

34	The t(11;22)(p15.5;q11.23) in a retroperitoneal rhabdoid tumor also includes a regional deletion distal to CRYBB2 on 22q. *Genes Chromosomes and Cancer*, **1995**, 13, 145-50	5	17
33	The p53 gene and its role in human brain tumors. *Glia*, **1995**, 15, 308-27	9	156
32	Structure, chromosomal localization, and expression of 12 genes of the MAGE family. *Immunogenetics*, **1994**, 40, 360-9	3.2	508
31	A new highly polymorphic DNA restriction site marker in the 5Sregion of the human tyrosine hydroxylase gene (TH) detecting loss of heterozygosity in human embryonal rhabdomyosarcoma. *Human Genetics*, **1994**, 93, 349-50	6.3	9
30	Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. *Nature Genetics*, **1994**, 8, 171-6	36.3	292
29	Molecular sublocalization and characterization of the 11;22 translocation breakpoint in a malignant rhabdoid tumor. *Genomics*, **1994**, 19, 433-40	4.3	19
28	A genetic linkage map with 29 loci spanning human chromosome 13q. *Genomics*, **1993**, 16, 515-9	4.3	1
27	Mutation and expression of the p53 gene in malignant melanoma cell lines. *International Journal of Cancer*, **1993**, 54, 693-9	7.5	76
26	Homozygous inactivation of WT1 in a WilmsStumor associated with the WAGR syndrome. *Genes Chromosomes and Cancer*, **1993**, 7, 131-6	5	25
25	Tumors and developmental anomalies associated with Wilms tumor. *Medical and Pediatric Oncology* , **1993**, 21, 199-204		5
24	Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. *Human Genetics*, **1993**, 92, 169-74	6.3	107
23	Characterization of polymorphic and monomorphic loci for chromosome 11p15.5. *Mammalian Genome*, **1993**, 4, 451-3	3.2	
22	Accumulation of genetic defects during astrocytoma progression. *Cancer*, **1992**, 70, 1788-93	6.4	47
21	Genetics of the malignant progression of astrocytoma. *Journal of Cellular Biochemistry*, **1991**, 46, 3-8	4.7	37
20	Microdissection of chromosome band 11p15.5: characterization of probes mapping distal to the HBBC locus. *Genes Chromosomes and Cancer*, **1991**, 3, 108-16	5	10
19	Charles S. Mott Prize. Recessive mutations in the causation of human cancer. *Cancer*, **1991**, 67, 2431-5	6.4	9
18	Molecular genetics in the pathology and diagnosis of retinoblastoma. *Brain Pathology*, **1990**, 1, 25-32	6	13
17	Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression. *Advances in Cancer Research*, **1990**, 54, 25-62	5.9	64

16	Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. *Nature*, **1990**, 343, 774-8	50.4	1174
15	Loss of genetic information in central nervous system tumors common to children and young adults. *Genes Chromosomes and Cancer*, **1990**, 2, 94-102	5	96
14	Structural alterations at the putative retinoblastoma locus in some human leukemias and preleukemia. *Cancer Genetics and Cytogenetics*, **1990**, 49, 15-23		24
13	Molecular differential pathology of rhabdomyosarcoma. *Genes Chromosomes and Cancer*, **1989**, 1, 23-35	5	187
12	Familial predisposition to WilmsStumour does not map to the short arm of chromosome 11. *Nature*, **1988**, 336, 374-6	50.4	231
11	Retinoblastoma and the progression of tumor genetics. *Trends in Genetics*, **1988**, 4, 125-8	8.5	73
10	Tumor suppressors: recessive mutations that lead to cancer. *Cell*, **1988**, 53, 173-4	56.2	100
9	Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. *DNA and Cell Biology*, **1987**, 6, 283-95		141
8	Retinoblastoma and osteosarcoma: the prototypic cancer family. *Pediatrics International*, **1987**, 29, 526-33	1.2	7
7	Recessive mutant genes predisposing to human cancer. *Mutation Research - Reviews in Genetic Toxicology*, **1986**, 168, 3-14		95
6	The genetic basis of neoplasia: the retinoblastoma paradigm. *Trends in Genetics*, **1986**, 2, 299-300	8.5	13
5	Prediction of familial predisposition to retinoblastoma. *New England Journal of Medicine*, **1986**, 314, 1201-7	59.2	105
4	Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. *Nature*, **1985**, 316, 330-4	50.4	493
3	Homozygosity of chromosome 13 in retinoblastoma. *New England Journal of Medicine*, **1984**, 310, 550-3	59.2	253
2	Characterization of dominant hamster cell mutants resistant to oxygenated sterols. *Somatic Cell Genetics*, **1982**, 8, 557-74		4
1	Elevation of HeLa cell 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by glucocorticoids: possible relationship to the cell cycle. *Journal of Cellular Physiology*, **1979**, 98, 199-211	7	24